Whistleblower lawyers are no stranger to facing off against formidable defense teams.

But on Thursday afternoon, lawyers for a pair of qui tam plaintiffs in a long-running False Claims Act suit who claim that Gilead Sciences Inc. improperly received hundreds of millions of dollars in government reimbursements for adulterated HIV drugs will face off against an unusual opponent: Lawyers from the U.S. Department of Justice.